HEREDITARY ANGIOEDEMA: CLINICAL CHARACTERISTICS AND CURRENT THERAPEUTIC APPROACHES
Abstract
Hereditary angioedema (HAE) is a condition characterized by recurrent edema caused by the dysfunction of bradykinin production. Advances in understanding the pathophysiology of this disease have changed the diagnostic approach, acute management and prophylaxis. Optimal treatment now combines early diagnosis, targeted therapy and patient education. This narrative review provides an overview of current evidence regarding the clinical presentation, treatment options and promising new therapies for HAE. A systematic search of the PubMed and Google Scholar databases was conducted using terms such as hereditary angioedema, therapeutics, C1 inhibitor deficiency, bradykinin and disease management. Additional relevant studies were identified by manually reviewing reference lists and citations. The basis for effective treatment is an accurate diagnosis based on clinical symptoms, family history, and laboratory test results. On-demand treatment, such as C1 esterase inhibitor (C1-INH), icatibant, and ecallantide provides rapid symptomatic control. Long-term prophylaxis with agents such as lanadelumab, berotralstat or plasma-derived C1 esterase inhibitor (pdC1-INH) significantly reduces the frequency of attacks and improves patients’ quality of life. New data confirm that modern biologic therapies can maintain disease control with a favorable safety profile. Current HAE treatment strategies emphasize personalized prophylaxis, adequate intervention in acute attacks and continuous patient education. Combining modern therapies with individual patient preferences improves daily functioning, mental well-being and overall prognosis.
References
Banerji, A., Riedl, M. A., Bernstein, J. A., Cicardi, M., Longhurst, H. J., Zuraw, B. L., Busse, P. J., Anderson, J., Magerl, M., Martinez-Saguer, I., Davis-Lorton, M., Zanichelli, A., Li, H. H., Craig, T., Jacobs, J., Johnston, D. T., Shapiro, R., Yang, W. H., Lumry, W. R., … Maurer, M. (2018). Effect of Lanadelumab Compared with Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial. JAMA - Journal of the American Medical Association, 320(20), 2108–2121. https://doi.org/10.1001/JAMA.2018.16773,
Banta, E., Horn, P. & Craig, T. J. (2011). Response to ecallantide treatment of acute attacks of hereditary angioedema based on time to intervention: Results from the EDEMA clinical trials. Allergy and Asthma Proceedings, 32(4), 319–324. https://doi.org/10.2500/AAP.2011.32.3440,
Bernstein, J. A., Li, H. H., Craig, T. J., Manning, M. E., Lawo, J. P., Machnig, T., Krishnarajah, G. & Fridman, M. (2019). Indirect comparison of intravenous vs. subcutaneous C1-inhibitor placebo-controlled trials for routine prevention of hereditary angioedema attacks. Allergy, Asthma and Clinical Immunology, 15(1). https://doi.org/10.1186/S13223-019-0328-3,
Bork, K., Hardt, J. & Witzke, G. (2012). Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. Journal of Allergy and Clinical Immunology, 130(3), 692–697. https://doi.org/10.1016/j.jaci.2012.05.055
Bork, K., Machnig, T., Wulff, K., Witzke, G., Prusty, S. & Hardt, J. (2020). Clinical features of genetically characterized types of hereditary angioedema with normal C1 inhibitor: a systematic review of qualitative evidence. Orphanet Journal of Rare Diseases, 15(1). https://doi.org/10.1186/S13023-020-01570-X,
Busse, P. J. & Christiansen, S. C. (2020). Hereditary Angioedema. The New England Journal of Medicine, 382(12), 1136–1148. https://doi.org/10.1056/NEJMRA1808012
Busse, P. J., Christiansen, S. C., Riedl, M. A., Banerji, A., Bernstein, J. A., Castaldo, A. J., Craig, T., Davis-Lorton, M., Frank, M. M., Li, H. H., Lumry, W. R. & Zuraw, B. L. (2021). US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema. Journal of Allergy and Clinical Immunology: In Practice, 9(1), 132-150.e3. https://doi.org/10.1016/j.jaip.2020.08.046
Buttgereit, T., Vera, C., Weller, K., Gutsche, A., Grekowitz, E. M., Aykanat, S., Wahn, V., Krüger, R., Maurer, M. & Magerl, M. (2021). Lanadelumab Efficacy, Safety, and Injection Interval Extension in HAE: A Real-Life Study. Journal of Allergy and Clinical Immunology: In Practice, 9(10), 3744–3751. https://doi.org/10.1016/j.jaip.2021.04.072
Caballero, T. (2021). Treatment of Hereditary Angioedema. Journal of Investigational Allergology & Clinical Immunology, 31(1), 1–16. https://doi.org/10.18176/JIACI.0653
Caballero, T., Maurer, M., Longhurst, H. J., Aberer, W., Bouillet, L., Fabien, V., Grumach, A. S., Bygum, A., Blanchard Delaunay, C., Boccon-Gibod, I., Coppere, B., Du Thanh, A., Dzviga, C., Fain, O., Goichot, B., Gompel, A., Guez, S., Jeandel, P., Kanny, G., … Garcez, T. (2016). Triggers and prodromal symptoms of angioedema attacks in patients with hereditary angioedema. Journal of Investigational Allergology and Clinical Immunology, 26(6), 383–386. https://doi.org/10.18176/JIACI.0102,
Cicardi, M, Banerji, A., Bracho, F., Malbrán, A., Rosenkranz, B., Riedl, M., Bork, K., Lumry, W., Aberer, W., Bier, H., Bas, M., Greve, J., Hoffmann, T. K., Farkas, H., Reshef, A., Ritchie, B., Yang, W., Grabbe, J., Kivity, S., … Fan, W.-T. (2010). Icatibant, a New Bradykinin-Receptor Antagonist, in Hereditary Angioedema. N Engl J Med, 363, 532–573. https://doi.org/10.1056/NEJMoa0906393
Cicardi, Marco, Aberer, W., Banerji, A., Bas, M., Bernstein, J. A., Bork, K., Caballero, T., Farkas, H., Grumach, A., Kaplan, A. P., Riedl, M. A., Triggiani, M., Zanichelli, A. & Zuraw, B. (2014). Classification, diagnosis, and approach to treatment for angioedema: Consensus report from the Hereditary Angioedema International Working Group. Allergy: European Journal of Allergy and Clinical Immunology, 69(5), 602–616. https://doi.org/10.1111/ALL.12380,
Craig, T. J., Bewtra, A. K., Bahna, S. L., Hurewitz, D., Schneider, L. C., Levy, R. J., Moy, J. N., Offenberger, J., Jacobson, K. W., Yang, W. H., Eidelman, F., Janss, G., Packer, F. R., Rojavin, M. A., Machnig, T., Keinecke, H. O. & Wasserman, R. L. (2011). C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks--final results of the I.M.P.A.C.T.2 study. Allergy, 66(12), 1604–1611. https://doi.org/10.1111/J.1398-9995.2011.02702.X
Craig, T., Zuraw, B., Longhurst, H., Cicardi, M., Bork, K., Grattan, C., Katelaris, C., Sussman, G., Keith, P. K., Yang, W., Hébert, J., Hanzlikova, J., Staubach-Renz, P., Martinez-Saguer, I., Magerl, M., Aygören-Pürsün, E., Farkas, H., Reshef, A., Kivity, S., … Jacobs, I. (2019). Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks. Journal of Allergy and Clinical Immunology: In Practice, 7(6), 1793-1802.e2. https://doi.org/10.1016/j.jaip.2019.01.054
Craig, Timothy J., Levy, R. J., Wasserman, R. L., Bewtra, A. K., Hurewitz, D., Obtułowicz, K., Reshef, A., Ritchie, B., Moldovan, D., Shirov, T., Grivcheva-Panovska, V., Kiessling, P. C., Keinecke, H. O. & Bernstein, J. A. (2009). Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. Journal of Allergy and Clinical Immunology, 124(4), 801–808. https://doi.org/10.1016/j.jaci.2009.07.017
Craig, Timothy J., Reshef, A., Li, H. H., Jacobs, J. S., Bernstein, J. A., Farkas, H., Yang, W. H., Stroes, E. S. G., Ohsawa, I., Tachdjian, R., Manning, M. E., Lumry, W. R., Saguer, I. M., Aygören-Pürsün, E., Ritchie, B., Sussman, G. L., Anderson, J., Kawahata, K., Suzuki, Y., … Magerl, M. (2023). Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 401(10382), 1079–1090. https://doi.org/10.1016/S0140-6736(23)00350-1
Donaldson, V. H. & Evans, R. R. (1963). A biochemical abnormality in hereditary angioneurotic edema. Absence of serum inhibitor of C′1-esterase. The American Journal of Medicine, 35(1), 37–44. https://doi.org/10.1016/0002-9343(63)90162-1
Farkas, H., Zotter, Z., Csuka, D., Szabó, E., Nébenfåhrer, Z., Temesszentandrási, G., Jakab, L., Varga, L., Harmat, G. & Karádi, I. (2012). Short-term prophylaxis in hereditary angioedema due to deficiency of the C1-inhibitor - A long-term survey. Allergy: European Journal of Allergy and Clinical Immunology, 67(12), 1586–1593. https://doi.org/10.1111/ALL.12032,
Farkas, Henriette. (2016). Icatibant as acute treatment for hereditary angioedema in adults. Expert Review of Clinical Pharmacology, 9(6), 779–788. https://doi.org/10.1080/17512433.2016.1182425
Farkas, Henriette & Kőhalmi, K. V. (2018). Icatibant for the treatment of hereditary angioedema with C1-inhibitor deficiency in adolescents and in children aged over 2 years. Expert Review of Clinical Immunology, 14(6), 447–460. https://doi.org/10.1080/1744666X.2018.1476851
Farkas, Henriette, Stobiecki, M., Peter, J., Kinaciyan, T., Maurer, M., Aygören-Pürsün, E., Kiani-Alikhan, S., Wu, A., Reshef, A., Bygum, A., Fain, O., Hagin, D., Huissoon, A., Jeseňák, M., Lindsay, K., Panovska, V. G., Steiner, U. C., Zubrinich, C., Best, J. M., … Sheridan, W. P. (2021). Long-term safety and effectiveness of berotralstat for hereditary angioedema: The open-label APeX-S study. Clinical and Translational Allergy, 11(4). https://doi.org/10.1002/CLT2.12035,
Germenis, A. E. & Speletas, M. (2016). Genetics of Hereditary Angioedema Revisited. Clinical Reviews in Allergy and Immunology, 51(2), 170–182. https://doi.org/10.1007/S12016-016-8543-X,
Jacobs, J. & Neeno, T. (2021). The importance of recognizing and managing a rare form of angioedema: hereditary angioedema due to C1-inhibitor deficiency. Postgraduate Medicine, 133(6), 639–650. https://doi.org/10.1080/00325481.2021.1905364,
Lee, A. (2021). Berotralstat: First Approval. Drugs, 81(3), 405–409. https://doi.org/10.1007/S40265-021-01475-4,
Levy, D., Caballero, T., Hussain, I., Reshef, A., Anderson, J., Baker, J., Schwartz, L. B., Cicardi, M., Prusty, S., Feuersenger, H., Pragst, I. & Manning, M. E. (2020). Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema. Pediatric, Allergy, Immunology, and Pulmonology, 33(3), 136–141. https://doi.org/10.1089/PED.2020.1143,
Levy, R. J., Lumry, W. R., McNeil, D. L., Li, H. H., Campion, M., Horn, P. T. & Pullman, W. E. (2010). EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Annals of Allergy, Asthma and Immunology, 104(6), 523–529. https://doi.org/10.1016/j.anai.2010.04.012
Longhurst, H., Cicardi, M., Craig, T., Bork, K., Grattan, C., Baker, J., Li, H. H., Reshef, A., Bonner, J., Bernstein, J. A., Anderson, J., Lumry, W. R., Farkas, H., Katelaris, C. H., Sussman, G. L., Jacobs, J., Riedl, M., Manning, M. E., Hebert, J., … Zuraw, B. L. (2017). Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor. New England Journal of Medicine, 376(12), 1131–1140. https://doi.org/10.1056/NEJMOA1613627,
Longhurst, H. J., Lindsay, K., Petersen, R. S., Fijen, L. M., Gurugama, P., Maag, D., Butler, J. S., Shah, M. Y., Golden, A., Xu, Y., Boiselle, C., Vogel, J. D., Abdelhady, A. M., Maitland, M. L., McKee, M. D., Seitzer, J., Han, B. W., Soukamneuth, S., Leonard, J., … Cohn, D. M. (2024). CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema. The New England Journal of Medicine, 390(5), 432–441. https://doi.org/10.1056/NEJMOA2309149
Lumry, W. R., Weller, K., Magerl, M., Banerji, A., Longhurst, H. J., Riedl, M. A., Lewis, H. B., Lu, P., Devercelli, G., Jain, G., Maurer, M., Hébert, J., Ritchie, B., Sussman, G., Yang, W. H., Martinez-Saguer, I., Staubach, P., Cicardi, M., Shennak, M., … Zafra, H. (2021). Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study. Allergy: European Journal of Allergy and Clinical Immunology, 76(4), 1188–1198. https://doi.org/10.1111/ALL.14680,
Lumry, W. R., Zuraw, B., Cicardi, M., Craig, T., Anderson, J., Banerji, A., Bernstein, J. A., Caballero, T., Farkas, H., Gower, R. G., Keith, P. K., Levy, D. S., Li, H. H., Magerl, M., Manning, M., Riedl, M. A., Lawo, J. P., Prusty, S., Machnig, T. & Longhurst, H. (2021). Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study. Orphanet Journal of Rare Diseases, 16(1). https://doi.org/10.1186/S13023-020-01658-4,
Magerl, M., Frank, M., Lumry, W., Bernstein, J., Busse, P., Craig, T., Martinez-Saguer, I., Riedl, M. A., Shapiro, R., Edelman, J., Williams-Herman, D., Wood, D. N., Feuersenger, H. & Rojavin, M. (2017). Short-term prophylactic use of C1-inhibitor concentrate in hereditary angioedema: Findings from an international patient registry. Annals of Allergy, Asthma and Immunology, 118(1), 110–112. https://doi.org/10.1016/j.anai.2016.10.006
Maurer, M., Aberer, W., Bouillet, L., Caballero, T., Fabien, V., Kanny, G., Kaplan, A., Longhurst, H. & Zanichelli, A. (2013). Hereditary Angioedema Attacks Resolve Faster and Are Shorter after Early Icatibant Treatment. PLoS ONE, 8(2). https://doi.org/10.1371/JOURNAL.PONE.0053773,
Maurer, M., Aygören-Pürsün, E., Banerji, A., Bernstein, J. A., Balle Boysen, H., Busse, P. J., Bygum, A., Caballero, T., Castaldo, A. J., Christiansen, S. C., Craig, T., Farkas, H., Grumach, A. S., Hide, M., Katelaris, C. H., Li, H. H., Longhurst, H., Lumry, W. R., Magerl, M., … Zuraw, B. (2021). Consensus on treatment goals in hereditary angioedema: A global Delphi initiative. Journal of Allergy and Clinical Immunology, 148(6), 1526–1532. https://doi.org/10.1016/j.jaci.2021.05.016
Maurer, M., Magerl, M., Betschel, S., Aberer, W., Ansotegui, I. J., Aygören-Pürsün, E., Banerji, A., Bara, N. A., Boccon-Gibod, I., Bork, K., Bouillet, L., Boysen, H. B., Brodszki, N., Busse, P. J., Bygum, A., Caballero, T., Cancian, M., Castaldo, A., Cohn, D. M., … Craig, T. (2022). The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update. Allergy, 77(7), 1961–1990. https://doi.org/10.1111/ALL.15214
Moore, L. (2024). Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks. Pediatrics, 154(Suppl 4), S56–S56. https://doi.org/10.1542/PEDS.2024-069114NG
Nowicki, R., Grubska-Suchanek, E., Porębski, G., Kowalski, M. L., Jahnz-Różyk, K., Matuszewski, T., Rudnicka, L., Kulus, M., Barańska-Rybak, W., Czajkowski, R., Doniec, Z., Kowalewski, C., Kręcisz, B., Lange, M., Narbutt, J., Olszewska, M., Sokołowska-Wojdyło, M., Szczerkowska-Dobosz, A., Śpiewak, R., … Wilkowska, A. (2020). Angioedema. Interdisciplinary diagnostic and therapeutic recommendations of the Polish Dermatological Society (PTD) and Polish Society of Allergology (PTA). Alergologia Polska - Polish Journal of Allergology, 7(3), 162–170. https://doi.org/10.5114/PJA.2020.99244
Osler, W. (2010). Landmark Publication from The American Journal of the Medical Sciences. The American Journal of the Medical Sciences, 339(2), 175–178. https://doi.org/10.1097/maj.0b013e3181b2803f
Pappalardo, E., Cicardi, M., Duponchel, C., Carugati, A., Choquet, S. & Tosi, M. (2000). Frequent de novo mutations and exon deletions in the Clinhibitor gene of patients with angioedema. Journal of Allergy and Clinical Immunology, 106(6), 1147–1154. https://doi.org/10.1067/MAI.2000.110471,
Pedrosa, M., Phillips-Angles, E., López-Lera, A., López-Trascasa, M. & Caballero, T. (2016). Complement Study Versus CINH Gene Testing for the Diagnosis of Type I Hereditary Angioedema in Children. Journal of Clinical Immunology, 36(1), 16–18. https://doi.org/10.1007/S10875-015-0222-9,
Petersen, R. S., Bordone, L., Riedl, M. A., Tachdjian, R., Craig, T. J., Lumry, W. R., Manning, M. E., Bernstein, J. A., Raasch, J., Zuraw, B. L., Deng, Y., Newman, K. B., Alexander, V. J., Lui, C., Schneider, E. & Cohn, D. M. (2024). A phase 2 open-label extension study of prekallikrein inhibition with donidalorsen for hereditary angioedema. Allergy: European Journal of Allergy and Clinical Immunology, 79(3), 724–734. https://doi.org/10.1111/ALL.15948,
Porębski, G., Gocki, J., Juchacz, A., Kucharczyk, A., Matuszewski, T., Olejniczak, K., Sokołowska, M., Stobiecki, M., Trębas-Pietraś, E. & Obtułowicz, K. (2018). Management of hereditary angioedema with C1 inhibitor-deficiency – consensus statement of the HAE Section of the Polish Society of Allergology. Part II: treatment, follow-up and special situations. Alergologia Polska - Polish Journal of Allergology, 5(2), 109–120. https://doi.org/10.5114/PJA.2018.76680
Reshef, A., Hsu, C., Katelaris, C. H., Li, P. H., Magerl, M., Yamagami, K., Guilarte, M., Keith, P. K., Bernstein, J. A., Lawo, J. P., Shetty, H., Pollen, M., Wieman, L. & Craig, T. J. (2025). Long-term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open-label extension study. Allergy: European Journal of Allergy and Clinical Immunology, 80(2), 545–556. https://doi.org/10.1111/ALL.16351,
Reshef, A., Prematta, M. J. & Craig, T. J. (2013). Signs and symptoms preceding acute attacks of hereditary angioedema: Results of three recent surveys. Allergy and Asthma Proceedings, 34(3), 261–266. https://doi.org/10.2500/AAP.2013.34.3663,
Riedl, M. A., Tachdjian, R., Lumry, W. R., Craig, T., Karakaya, G., Gelincik, A., Stobiecki, M., Jacobs, J. S., Gokmen, N. M., Reshef, A., Gompels, M. M., Manning, M. E., Bordone, L., Newman, K. B., Treadwell, S., Wang, S., Yarlas, A. & Cohn, D. M. (2024). Efficacy and Safety of Donidalorsen for Hereditary Angioedema. New England Journal of Medicine, 391(1), 21–31. https://doi.org/10.1056/NEJMOA2402478,
Sinnathamby, E. S., Issa, P. P., Roberts, L., Norwood, H., Malone, K., Vemulapalli, H., Ahmadzadeh, S., Cornett, E. M., Shekoohi, S. & Kaye, A. D. (2023). Hereditary Angioedema: Diagnosis, Clinical Implications, and Pathophysiology. Advances in Therapy, 40(3), 814–827. https://doi.org/10.1007/S12325-022-02401-0
Zarnowski, J., Rabe, M., Kage, P., Simon, J. C. & Treudler, R. (2021). Prophylactic Treatment in Hereditary Angioedema Is Associated with Reduced Anxiety in Patients in Leipzig, Germany. International Archives of Allergy and Immunology, 182(9), 819–826. https://doi.org/10.1159/000514973,
Zuraw, B., Cicardi, M., Levy, R. J., Nuijens, J. H., Relan, A., Visscher, S., Haase, G., Kaufman, L. & Hack, C. E. (2010). Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology, 126(4). https://doi.org/10.1016/j.jaci.2010.07.021
Zuraw, B. L. & Christiansen, S. C. (2016). HAE Pathophysiology and Underlying Mechanisms. Clinical Reviews in Allergy & Immunology 2016 51:2, 51(2), 216–229. https://doi.org/10.1007/S12016-016-8561-8
Zuraw, B., Lumry, W. R., Johnston, D. T., Aygören-Pürsün, E., Banerji, A., Bernstein, J. A., Christiansen, S. C., Jacobs, J. S., Sitz, K. V., Gower, R. G., Gagnon, R., Wedner, H. J., Kinaciyan, T., Hakl, R., Hanzlíková, J., Anderson, J. T., McNeil, D. L., Fritz, S. B., Yang, W. H., … Riedl, M. A. (2021). Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial. Journal of Allergy and Clinical Immunology, 148(1), 164-172.e9. https://doi.org/10.1016/j.jaci.2020.10.015
Views:
59
Downloads:
25
Copyright (c) 2025 Alicja Nowik, Julia Mazurek, Joanna Kośka, Julia Załęcka, Katarzyna Moliszewska, Paweł Kukiełka, Michał Błaszkiewicz, Kacper Dywan, Martyna Musiorska
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
